Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

– Company to present new data at AASLD from Phase 2 chronic hepatitis B and chronic hepatitis delta clinical trials –– Company expanding strategic focus to autoimmune diseases and immuno-oncology –– Jennifer Towne, Ph.D., appointed as Executive Vice President and Chief Scientific Officer, effective November 6, 2023...

Related Keywords

Boston ,Massachusetts ,United States ,Brii Biosciences ,Carly Scaduto ,Jennifer Towne ,Amgen ,Human Services ,Development Expenses ,Xencor Inc ,Vaccine Trials Network ,Biomedical Advanced Research ,Nasdaq ,Company Phase ,Division Of Chemical ,Administration For Strategic Preparedness ,Department Of Health ,Janssen Pharmaceutical Companies Of Johnson ,Exchange Commission ,Teamvir Vir Biotechnology Inc ,National Institute Of Allergy ,National Institutes Of Health ,Development Authority ,Melinda Gates Foundation ,Vir Biotechnology Inc ,Nuclear Medical Countermeasures ,Alnylam Pharmaceuticals Inc ,Us Department Of Health ,Executive Vice President ,Chief Scientific Officer ,Teamvir Vir Biotechnology ,Marianne De Backer ,Chief Executive ,Chronic Hepatitis Delta ,American Association ,Liver Diseases ,Immunodeficiency Virus ,National Institute ,Infectious Diseases ,National Institutes ,Strategic Preparedness ,Project Nextgen ,Nuclear Medical ,Janssen Pharmaceutical Companies ,Cash Equivalents ,Administrative Expenses ,Income Taxes ,Enhanced Stabilization Chemistry Plus ,Alnylam Pharmaceuticals ,Vir Biotechnology ,Private Securities Litigation Reform Act ,Consolidated Statements ,Media Relations ,